Investment
Features
FeesSafety
Academy
More
Pluang+

Compare McKesson Corporation (MCK) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance

McKesson CorporationTrade
GraniteShares 2x Long NVDA Daily ETFTrade

Price performance (Past 24H)

Key statistics

McKesson Corporation vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? McKesson Corporation trades at $882.6 (market cap $105.14B), while GraniteShares 2x Long NVDA Daily ETF trades at $36.27. The key difference: McKesson Corporation pays a 0.42% dividend while GraniteShares 2x Long NVDA Daily ETF pays none. Which is the better fit depends on your goals.

MCKNVDL
Market Cap
$105.14B
Sector
HealthLeveraged / Inverse
52-Week High
$995.69$43.02
52-Week Low
$659.01$21.76
Enterprise Value
$111.67B
Dividend Yield
0.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

McKesson Corporation

McKesson (MCK) trades at $889.01, up 1.04% today, with a bullish technical outlook and strong institutional support. Recent Q1 2027 earnings beat expectations, with EPS of $9.93 versus $9.56, driven by specialty drug growth and oncology performance. Revenue reached $359.05B in 2025, with net income of $3.30B, though margins remain thin. The company raised full-year guidance, reflecting operational momentum.

The stock offers upside to the consensus price target of $990.67, supported by 80% analyst buy ratings. Key risks include reliance on pharmaceutical distribution margins, regulatory pressures, and competitive threats. Earnings consistency and cost discipline are critical for sustaining valuation multiples amid healthcare sector volatility.

GraniteShares 2x Long NVDA Daily ETF

NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $36.32, up 5.7% in 24 hours, reflecting strong bullish momentum from its underlying asset NVIDIA. Technical indicators show a bullish trend with moving averages supporting upward movement, though the RSI suggests mild overbought conditions. Recent news highlights NVDL's leveraged exposure to NVIDIA's AI-driven growth, with the ETF capturing amplified returns from NVDA's performance, including a 12.66% year-to-date gain as of June 8, 2026, per 24/7 Wall Street.

The outlook for NVDL is tied to NVIDIA's continued dominance in AI chips, with potential for significant gains during bullish phases but high volatility risks due to daily reset leverage. Key risks include compounded losses during NVDA downturns, as seen in a 12% single-day drop on June 5, 2026. Investors should weigh the ETF's amplified returns against its inherent decay in volatile markets.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK

About GraniteShares 2x Long NVDA Daily ETF

NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.

Read more on NVDL